Evidence map›Paper›PMID 33779758›Full record

ReviewThe Journal of pharmacy and pharmacology2021

Isatis indigotica: a review of phytochemistry, pharmacological activities and clinical applications.

Qiong Chen, Hai-Yue Lan, Wei Peng, Khalid Rahman, Qing-Chun Liu, Xin Luan, Hong Zhang

Abstract readReview
In one paragraph

Review in The Journal of pharmacy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Genetic Analysis and Fingerprint Construction forCurrent issues in molecular biology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Inhibitory Efficacy of Main Components ofInternational journal of molecular sciences · 2024
    Article
  16. Effect of miR-17 onFrontiers in veterinary science · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiong ChenInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hai-Yue LanInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wei PengSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Khalid RahmanSchool of Pharmacy and Biomolecular Sciences, Faculty of Science, Liverpool John Moores University, Liverpool, England, UK.
Qing-Chun LiuDepartment of Medicine, Chengdu Brilliant Pharmaceutical Co. Ltd. , Chengdu, China.
Xin LuanInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hong ZhangInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0002-6191-0046

Funding

National key R & D program for key research project of modernization of traditional Chinese medicine 2019YFC1711602National Key Subject of Drug Innovation 2019ZX09201005-007National Natural Science Foundation of China 81773941Xinglin Scholar Discipline Promotion Talent Program of Chengdu University of Traditional Chinese Medicine BSH2018006
6 · The paper itself

Abstract

objectivesIsatis indigotica Fort. (I. indigotica) is an herbaceous plant belonging to Cruciferae family. Its leaf (IIL) and root (IIR) are commonly used in traditional Chinese medicines (TCMs) with good clinical efficacies such as clearing away heat and detoxification, cooling blood and reducing swelling. This review aimed to provide a systematic summary on the phytochemistry, pharmacology and clinical applications of I. indigotica. KEY

findingsThis plant contains alkaloids, organic acids, flavonoids, lignans, nucleosides, amino acids, and steroids. Previous pharmacological researches indicated that I. indigotica possesses promising antivirus, antibacterial, immunoregulatory, anti-inflammation, and cholagogic effects. Importantly, it can inhibit various viruses, such as influenza, hepatitis B, mumps, herpes simplex, cytomegalovirus, and coxsachievirus. Clinically, it is frequently used to treat various viral diseases like viral influenza, parotitis and viral hepatitis. Consequently, I. indigotica may be beneficial for the prevention and treatment of coronavirus disease 2019 (COVID-19). SUMMARY: This paper reviewed the chemical constituents, pharmacological effects and clinical applications of I. indigotica which may guide further research and application of this plant.

Indexed as

COVID-19 Drug TreatmentDrugs, Chinese HerbalIsatisAntiviral AgentsCOVID-19HumansImmunologic FactorsMedicine, Chinese TraditionalSARS-CoV-2Treatment OutcomeAntiviral AgentsDrugs, Chinese HerbalImmunologic Factorsclinical applicationIsatis indigoticapharmacologyphytochemistrytraditional Chinese medicine

Identifiers

PMID33779758
PMCPMC8249990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.